BioCentury
ARTICLE | Top Story

BMS teams with uniQure for CV gene therapies

April 7, 2015 12:22 AM UTC

In less than a year, uniQure N.V. (NASDAQ:QURE) has parlayed its EUR 3 million ($4 million) acquisition of InoCard GmbH into an expansive deal with Bristol-Myers Squibb Co. (NYSE:BMY). News of the deal sent uniQure's shares up $10.75 (47%) to $33.61 on Monday.

uniQure will grant BMS exclusive access to its gene therapy technology platform for up to 10 targets, including but not limited to cardiovascular disease targets. The deal includes uniQure's program targeting S100 calcium binding protein A1 ( S100A1), which uniQure gained through its acquisition of InoCard last August. uniQure's AAV-S100A1 therapy, an adeno-associated virus expressing S100A1, is in preclinical testing to treat congestive heart failure (CHF). uniQure expects clinical testing to start in 2017. ...